Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293293 | 0.85 | MAPT (0.39) | MAPTGAAALDH1A1TDP1KDM4E | |
| SCHEMBL14596452 | 0.73 | ALDH1A1 (0.42) | MAPTGAAALDH1A1TDP1KDM4E | |
| SCHEMBL28803244 | 0.71 | MAPT (0.36) | MAPTGAAALDH1A1TDP1KDM4E | |
| SCHEMBL29367162 | 0.71 | — | — | |
| SCHEMBL928800 | 0.69 | CASP1 (0.52) | MAPTGAATDP1LMNAMEN1 | |
| SCHEMBL30386718 | 0.69 | CASP1 (0.52) | MAPTGAATDP1LMNAMEN1 | |
| SCHEMBL9870304 | 0.68 | MAPT (0.50) | MAPTGAAALDH1A1TDP1KDM4E | |
| Ammonia Solution, Strong SCHEMBL25301697 | 0.68 | — | — | |
| SCHEMBL873623 | 0.67 | TSHR (0.43) | MAPTGAAALDH1A1TDP1KDM4E | |
| SCHEMBL29665710 | 0.67 | TSHR (0.43) | MAPTGAAALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | disclosed |
| US-10245254-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
| CN-101312977-B | Fused heterocyclic compounds useful as kinase modulators | BRISTOL MYERS SQUIBB CO | 2012-06-13 | — | — | CN | disclosed |
| CN-101312977-A | Fused heterocyclic compounds useful as kinase modulators | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | MAPT 4492/4885GAA 142/4885ALDH1A1 959/4885 |
| US-10245254-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | MAPT 4492/4885GAA 142/4885ALDH1A1 959/4885 |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | MAPT 4520/4885GAA 164/4885ALDH1A1 968/4885 |
| US-11013724-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | MAPT 4520/4885GAA 164/4885ALDH1A1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.